Drugmakers must complete a gap analysis and submit their compliance strategy to extend Schedule M implementation. Small and medium manufacturers, with a turnover of less than ₹250 crore, have until December 31 to comply. They need to submit their upgrade plans within three months.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/y3BVLIr
via IFTTT
No comments:
Post a Comment